Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Obinutuzumab or Acalabrutinib in Previously Untreated CLL
NCT06428019Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc.. Started Aug 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06428019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428019.